Skip to main content

Table 2 Change of parameters

From: Dipeptidyl peptidase 4 inhibitor linagliptin can decrease the dosage of erythropoiesis-stimulating agents in patients on hemodialysis

 

Before treatment

Post treatment

Wilcoxon signed-rank test

Dosage of DA

23.9 ± 21.2

11.3 ± 9.7

P < 0.05

ERI

2.27 ± 2.08

1.04 ± 0.90

P < 0.05

Hb

10.8 ± 0.6

11.4 ± 0.9

NS

hs-CRP

5335 ± 6495

2568 ± 4059

NS

TSAT

24.2 ± 6.5

31.9 ± 11.0

NS

Ferritin

264.7 ± 334.6

249.8 ± 224.2

NS

Albumin

3.6 ± 0.4

3.6 ± 0.3

NS

WBC

5789 ± 1282

5687 ± 2121

NS

Plt

15.6 ± 6.4

15.2 ± 6.1

NS

  1. DA darbepoetin alfa, ERI erythropoiesis-stimulating agent-resistant index, Hb hemoglobin, TSAT transferrin saturation, WBC white blood cells count, Plt platelet count
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us